Description: This discussion at the SOA 1967 Annual Meeting covers three topics. First is the Carter Commission Report that recommends radical changes to the Canadian tax system. Second is a report on U.S. federal government activities in the health market. Third is an update on variable annuities.

Description: Explore cutting-edge advancements in virtual care, including remote patient monitoring and care delivery in the metaverse, which build on the foundation that pandemic-era telehealth built. Gain a deep understanding of how these innovations are set to shape the future of telehealth and healthcare more broadly. By attending the session, you will be equipped with a roadmap of the key trends and opportunities in virtual care, and be able to identify potential challenges and solutions for their own organizations in leveraging these new tools.

Description: Delve into the factors contributing to the rapid growth of high-cost medical treatments and how payers can manage the financial exposure that comes with them. Learn about the current and near-future state of million-dollar medical costs, as well as the trends shaping the industry. By attending the session, you will have a better understanding of the underlying drivers of high-cost treatments and will be equipped with practical strategies for mitigating their financial impact, including risk management techniques, cost containment measures, and new payment models. Additionally, you will be able to identify key considerations for implementing these strategies in their own organizations.

Description: 1994 SOA Meeting, San Antonio. This session provided an update from representatives of the IRS and the Department of the Treasury on several topics including: 1. PBGC issues. 2. Social Security issues. 3. Health care issues. 4. Title I issues. 5. Broad principles underlying some remedial amendment period issues.

Description: Summary of the December 2003 NAIC Meeting

Description: This panel discussion is from the 1991 Meeting of the Society of Actuaries, held May 16-17 in New York. The panelists debunk myths, the conventional wisdom that actuaries have no place in the public policy arena, whether because the profession is too small to influence public policymakers, or legislators just don't want to hear from professionals whose work is so technical in nature and specialized in its application, or that It's not really necessary to become too involved in public policymaking, because what goes on in legislatures just doesn't affect actuaries’ day-to-day working lives. The panelists provide insights on lending actuarial expertise to policymaking debates. Discussion from participants is included. From the Record of Society of Actuaries, Volume 17, No. 2.

Description: This article talks about assets and liabilities as they related to Sarbanes-Oxley legislation. From Small Talk Newsletter, November 2005, Issue No. 25.

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: These are the discussant comments for the concurrent session 4A: Longevity in the Public Eye from the January 4-6, 2017 Living to 100 Symposium in Orlando.

Description: In this session 2PD of the 2004 Valuation Actuary Symposium panelists share their perspectives on valuation-actuary-related issues, including the hot issues from a regulatory concern.